| Outcome Measures: |
Primary: Change in HbA1c, Mean change in glycosylated hemoglobin (HbA1c) from baseline to Week 24, From baseline to Week 24 | Secondary: Patients with HbA1c <7%, Number of patients reaching HbA1c \<7 % at the end of Week 24, At Week 24|Change in 2-hour Post prandial glucose (PPG), Change in 2-hour PPG from baseline to Week 24, From baseline to Week 24|Change in body weight, Change in body weight from baseline to Week 24, From baseline to Week 24|Patients with HbA1c <7% with no body weight gain and no hypoglycemia, Number of patients reaching HbA1c \<7% with no body weight gain and no hypoglycemia at the end of Week 24, At Week 24|Change in Fasting Plasma Glucose, Mean change in FPG from baseline to Week 24, From baseline to Week 24|Adverse events (AE), Number of AEs, Up to 33 weeks|Patients with HbA1c <7% with no body weight gain, Number of patients reaching HbA1c \<7% with no body weight gain at the end of Week 24, At Week 24|Change in SMPG profiles, Change in 7-point self-monitoring plasma glucose (SMPG) profiles from baseline to Week 24, From baseline to Week 24
|
| Locations: |
Investigational Site Number 01, Bangalore, 560092, India|Investigational Site Number 012, Belgaum, 590010, India|Investigational Site Number 013, Chennai, 600086, India|Investigational Site Number 017, Coimbatore, 641009, India|Investigational Site Number 06, Hyderabad, 500063, India|Investigational Site Number 07, Hyderabad, 500072, India|Investigational Site Number 08, Jaipur, India|Investigational Site Number 04, Kolkata, 700107, India|Investigational Site Number 018, Lucknow, India|Investigational Site Number 014, Madurai, 625020, India|Investigational Site Number 05, Nasik, 422002, India|Investigational Site Number 010, New Delhi, 110029, India|Investigational Site Number 016, Pune, 411040, India
|
